Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer
Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Summary
To observe the incidence of chemotherapy-induced myelosuppression and the safety of Trilaciclib combined with mFOLFIRINOX in patients with advanced pancreatic cancer receiving first-line treatment.
Official title: A Single-arm, Exploratory Clinical Study of Trilaciclib Combined With mFOLFIRINOX Regimen in the Treatment of Patients With Advanced Pancreatic Cancer
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2024-01-20
Completion Date
2026-10-28
Last Updated
2024-02-23
Healthy Volunteers
No
Conditions
Interventions
Trilaciclib+mFOLFIRINOX
This was a single-arm, exploratory study of the combination of Trilaciclib and mFOLFIRINOX in patients with advanced pancreatic cancer receiving first-line therapy. Observed the incidence of chemotherapy-induced myelosuppression, and imaging was performed every four cycles to assess tumor response.
Locations (1)
The Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China